New Pill Cuts Cholesterol 60% Without Painful Injections

Millions of Americans battling stubborn high cholesterol just got their best news in years.

Researchers announced Wednesday that an experimental pill called enlicitide reduced artery-clogging cholesterol by as much as 60 percent in people who remained at high risk even while taking statins. The results appeared in the New England Journal of Medicine.

The breakthrough matters because it delivers the same powerful punch as existing injectable drugs, but in a form people actually want to use. Dr. Ann Marie Navar, the study's lead author from UT Southwestern Medical Center, said no other pill comes close to this level of cholesterol reduction.

The trial followed nearly 3,000 high-risk patients for a year. Those taking enlicitide saw dramatic drops in their LDL or bad cholesterol over six months, and the benefit held strong through twelve months. Best of all, they experienced no more side effects than people taking a placebo.

Heart disease kills more Americans than any other condition, and high LDL cholesterol is a leading culprit. While statins work well for many people, millions need extra help getting their cholesterol low enough to protect their hearts.

That help exists today in the form of PCSK9 inhibitor shots. These powerful drugs work brilliantly, but hardly anyone uses them. The shots are expensive, complicated to prescribe, and require people to inject themselves regularly.

Enlicitide works the same way as those shots, blocking a liver protein that stops the body from clearing cholesterol naturally. The difference is you swallow it with water on an empty stomach.

Merck funded the study and has already joined the FDA's fast-track approval program. If all goes well, the pill could reach pharmacies within months.

The Bright Side

Dr. William Boden of Boston University, who reviewed the research independently, called the evidence "compelling." He noted one important caveat: researchers haven't yet proven the pill prevents actual heart attacks, strokes, or deaths. That takes years to demonstrate.

But Merck is already running a massive 14,000-patient study to answer that exact question. And the logic is clear. We know lowering cholesterol this dramatically protects hearts. We just need time to prove this specific pill delivers those life-saving results.

For now, millions of people stuck between ineffective treatment and shots they won't take finally see a path forward. Effective treatment shouldn't require needles, high costs, or prescription headaches. Sometimes the best innovation is making what works actually usable.

The FDA's expedited review means answers are coming soon.